
Mesoblast Limited received the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards, recognizing its rapid growth and innovation. This follows the successful U.S. launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric acute graft versus host disease. The award highlights Mesoblast's transition to a commercial-stage biotech company and its focus on expanding its cell therapy portfolio and global partnerships. The company aims to deliver sustainable growth and long-term value for shareholders through ongoing development and commercialization efforts.
As of Nov 20, 2026 07:01 WIB, Mesoblast Limited (MESO) trades at USD 11.20 on Pluang, showing a 3.78% decline in the past day. The company holds a market cap of $1.54 billion and an enterprise value of $1.62 billion. Despite the recent award for leadership and growth, MESO's typical hold time on Pluang is 18 days, reflecting active investor interest.